Want to see ORGO full AI Analyst Report?
Top Page
Organogenesis Holdings
(NASDAQ:ORGO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.98
▼(-43.51% Downside)
Action:Reiterated
Date:10/06/26
The score is pulled down primarily by sharply weakened profitability and very weak technical trends (price below all major moving averages with negative MACD). Earnings-call guidance also signals substantial near-term revenue pressure and elevated execution/financing risk, partially offset by meaningful cost cuts, regulatory/clinical milestones, and notably improved operating and free cash flow.
Positive Factors
Cash Generation
Positive operating and free cash flow provide internal funding capacity despite reported losses. If maintained, stronger cash conversion can support ongoing operations, reduce reliance on external capital, and give management time to execute restructuring and commercial recovery plans.
Negative Factors
Revenue Contraction
The sharply reduced revenue outlook indicates that the business is undergoing a substantial demand and market reset rather than a routine fluctuation. Prolonged top-line weakness can limit operating leverage, weaken provider momentum, and make recovery dependent on successful execution in later quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Positive operating and free cash flow provide internal funding capacity despite reported losses. If maintained, stronger cash conversion can support ongoing operations, reduce reliance on external capital, and give management time to execute restructuring and commercial recovery plans.
Read all positive factors
Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$127.80M
Dividend YieldN/A
Average Volume (3M)763.76K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth6.50%
EPS Growth-613.22%
CountryUS
Employees854
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.82
Shares Outstanding128,674,550
10 Day Avg. Volume999,093
30 Day Avg. Volume763,758
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap3.70
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda-261.28
Forecast
1Y Price Target
$2.00Price Target Upside14.94% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$196.05M
Organogenesis Holdings Business Overview & Revenue Model
Company Description
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its adva...
How the Company Makes Money
Organogenesis makes money primarily by selling its regenerative medicine and biologic tissue products to healthcare providers and facilities for use in wound care and surgical applications. Revenue is generated through product sales in its core co...
Organogenesis Holdings Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Negative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.Positive Updates
Sequential Revenue and Volume Recovery
Net product revenue increased 18% quarter-over-quarter in Q2; Advanced Wound Care sales rose 23% sequentially and wound care unit volume grew 30% Q/Q, indicating measured improvement from Q1 trough.
Negative Updates
Severe Year-over-Year Revenue Decline
Net product revenue was $42.8 million in Q2, down 58% year-over-year; Advanced Wound Care revenue was $36.1 million, down 61% YoY; Surgical & Sports Medicine revenue was $6.7 million, down 18% YoY.
Read all updates
Q2-2026 Updates
Positive
Negative
Sequential Revenue and Volume Recovery
Net product revenue increased 18% quarter-over-quarter in Q2; Advanced Wound Care sales rose 23% sequentially and wound care unit volume grew 30% Q/Q, indicating measured improvement from Q1 trough.
Read all positive updates
Company Guidance
Organogenesis updated 2026 guidance calling for total net revenue of $179M–$215M (a 62%–68% YoY decline) — with Advanced Wound Care sales of $151M–$183M, Surgical & Sports Medicine $26M–$30M and $1.9M of grant income — and expects sequential improvement in Q3 and Q4 but a second‑half YoY revenue decline of roughly 64%–74%. Management expects improving adjusted EBITDA quarter‑to‑quarter, targeting nearly a 60% reduction in adjusted EBITDA loss in 2H vs 1H at the low end and >90% reduction at the high end (including positive adjusted EBITDA in Q4); it plans to cut operating expenses (ex‑COGS) ~32% YoY in 2026 and >40% YoY in 2H. Cost actions include a June workforce reduction of 138 employees (≈$18M annualized savings), March and June restructurings together expected to reduce annual operating expenses by >$32M, estimated 3Q/4Q savings of ~$7M and ~$9M respectively; cash was $46.8M at 6/30/26 with no debt, an ATM facility up to $75M, and management believes cash plus product cash flows will fund operations for at least the next 12 months.Organogenesis Holdings Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
62
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 456.54M | 563.03M | 482.04M | 433.14M | 450.89M | 467.36M |
| Gross Profit | 308.56M | 425.51M | 366.30M | 326.66M | 345.87M | 353.16M |
| EBITDA | -1.81M | 73.91M | 15.76M | 36.03M | 40.32M | 87.00M |
| Net Income | -90.23M | 37.03M | 861.00K | 4.95M | 15.53M | 94.20M |
Balance Sheet | ||||||
| Total Assets | 406.45M | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M |
| Cash, Cash Equivalents and Short-Term Investments | 46.10M | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M |
| Total Debt | 66.95M | 132.84M | 43.31M | 119.35M | 123.79M | 132.30M |
| Total Liabilities | 118.31M | 164.81M | 112.57M | 181.36M | 183.69M | 201.92M |
| Stockholders Equity | 288.13M | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M |
Cash Flow | ||||||
| Free Cash Flow | 20.84M | -24.46M | 4.18M | 6.55M | -9.04M | 30.76M |
| Operating Cash Flow | 31.97M | -10.31M | 14.21M | 30.92M | 24.86M | 61.98M |
| Investing Cash Flow | -11.13M | -14.15M | -10.03M | -24.36M | -33.90M | -31.22M |
| Financing Cash Flow | -47.73M | -17.36M | 27.64M | -5.50M | -2.20M | -1.04M |
Organogenesis Holdings Technical Analysis
Negative
1.74
Price Trends
1.45
Negative
1.92
Negative
2.45
Negative
Market Momentum
-0.14
Positive
24.62
Positive
21.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Negative. The current price of 1.74 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.45, and below the 200-day MA of 2.45, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 24.62 is Positive, neither overbought nor oversold. The STOCH value of 21.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORGO.
Organogenesis Holdings Risk Analysis
Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Organogenesis Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.45B | 103.44 | 2.13% | ― | 5.71% | ― | |
53 Neutral | $141.69M | -22.22 | -20.23% | ― | 20.89% | 40.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $463.01M | -13.53 | 123.11% | ― | 13.87% | 45.83% | |
49 Neutral | $242.60M | -5.82 | -376.95% | ― | ― | ― | |
48 Neutral | $127.80M | -1.21 | -24.23% | ― | 6.50% | -613.22% | |
42 Neutral | $5.32M | -0.91 | -53.56% | ― | 47.00% | 50.49% |
* Healthcare Sector Average
ORGO
Organogenesis Holdings
0.99
-3.29
-76.80%
LFCR
Lifecore Biomedical
6.40
-0.33
-4.90%
SNOA
Sonoma Pharmaceuticals
1.11
-2.89
-72.25%
PCRX
Pacira Pharmaceuticals
36.42
15.09
70.75%
EOLS
Evolus
7.01
-0.21
-2.91%
DERM
Journey Medical Corp
5.02
-3.00
-37.41%
Organogenesis Holdings Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Organogenesis Launches New $75 Million At-The-Market Offering
Neutral
Aug 6, 2026
On August 6, 2026, Organogenesis Holdings Inc. entered into an at-the-market sales agreement with BTIG, LLC and Citizens JMP Securities, LLC, allowing it to sell up to $75 million of its Class A common stock from time to time through these agents....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.